logo
Egan-Jones Supports Case for Urgent Board Renewal at Brookdale Senior Living Inc. and Recommends a Vote

Egan-Jones Supports Case for Urgent Board Renewal at Brookdale Senior Living Inc. and Recommends a Vote

Business Wire01-07-2025
NEW YORK--(BUSINESS WIRE)--Ortelius Advisors, L.P. ('Ortelius') today announced that independent proxy advisory firm, Egan-Jones Ratings Company ('Egan-Jones'), has recommended that stockholders vote FOR the election of all six Ortelius nominees to the Brookdale Senior Living Inc. (NYSE: BKD) ('Brookdale' or 'Company') Board of Directors, on the WHITE Ortelius proxy card, at the upcoming 2025 Annual Meeting of Stockholders. The recommendation from Egan-Jones builds on supportive commentary already published by Institutional Shareholder Services Inc. ('ISS') regarding Ortelius' campaign for change at Brookdale.
Peter DeSorcy, Managing Member of Ortelius, said:
'Egan-Jones has provided another critical, independent, and credible voice to the chorus advocating for urgent change at Brookdale. We appreciate the clarity of their recommendation to vote for ALL six of Ortelius' highly qualified nominees to unlock the significant value within Brookdale and end the history of underperformance.
As recognized by both Egan-Jones and ISS, a refreshed Board possessing the right skills and expertise is essential to rapidly advance a meaningful turnaround at Brookdale. This includes leading the process of selecting a new and highly qualified CEO, as well as moving quickly to sell underperforming assets and unlock long-term value for stockholders.
With the support of two independent proxy advisory firms, we urge our fellow Brookdale stockholders to vote FOR all six of the Ortelius nominees on the WHITE proxy card.'
In its report finding that Ortelius has presented a compelling case for change at Brookdale, Egan-Jones*:
Recognized the distinct and unique nature of Ortelius' strategy and confirmed the need for significant Board renewal to drive change:
'We believe that the current management and the Ortelius nominees propose strategies that are diametrically opposed to each other: management is determined that they will be able to grow out of their debt – something that seems unlikely given multiple years in a row of extremely low operating margins. On the other hand, Ortelius believes underperforming assets must be sold off to pay down debt and improve operating margins. We strongly believe that, to effectively execute a meaningful turnaround and unlock long-term value for shareholders, the full slate of Ortelius nominees should be elected.'
Validated Ortelius' criticisms about Brookdale's operating performance and Total Shareholder Return ('TSR'):
'The Company has not been able to recover after COVID, with the TSR from the beginning of 2020 through the end of 2024 sitting at -30%. Despite strong industry tailwinds, such as rising occupancy in senior housing and increasing demand due to changing demographics, BKD's TSR has remained stagnant. We believe that the Company's inability to capitalize on these market opportunities demonstrates the need to re-evaluate its current strategy.'
Concluded Brookdale has clearly underperformed its peers and faces an unsustainable debt burden which requires urgent action:
' [Brookdale]... has greatly underperformed NHC as well as the total market. Additionally, it is worth noting that BKD has not been able to recover to pre-covid returns but are instead down 30% over the 5-year period.'
'Given the company's inability to recover from COVID and their lagging occupancy rates compared to nationwide averages, we do not believe the Company will be able to grow itself out of debt.'
Supported Ortelius' assertion that Management's strategy is insufficient and unlikely to restore profitability at Brookdale:
'The Company's financial performance presents significant concerns, primarily due to high leverage and poor operational efficiency. With debt-to-enterprise value ratios consistently average over 90% over the past five years, BKD is heavily reliant on debt. Revenue growth is being offset by the Company's persistently low operating margin. In our view, the Company's weak balance sheet limits its financial flexibility and means to restore profitability.'
Confirmed that Ortelius' plan to sell underperforming properties is well conceived and viable:
'The Company believes it will be able to grow its way out of debt. Divesting non-core assets does not appear to be an option under the current board and management. In our view, their optimism about improving BKD's average occupancy rate comes too late, especially considering the excessive cash burn and mounting debt. We believe the Ortelius nominees are correct that assets will need to be sold off to generate cash, to pay off debt, invest in improved facilities, and re-align its strategy as a pure play company.'
Endorsed all six Ortelius nominees for their specific expertise and capacity to efficiently execute a turnaround at Brookdale:
'After reviewing available public information and engaging with both Brookdale's management team and Ortelius, Egan-Jones recommends shareholders vote FOR all six Ortelius nominees: Steven J. Insoft, Paula J. Poskon, Frank J. Small, Ivona Smith, Steven L. Vick, and Lori B. Wittman.'
'Ortelius' slate brings the right mix of skills and expertise across senior housing, REITs, finance, capital markets, and operational turnarounds.'
'We recommend shareholders vote FOR all six Ortelius nominees as they bring a viable strategy to a struggling company.'
Recommended 'Withhold' votes on long tenured Brookdale directors while only supporting the most recent additions to the incumbent Board:
'We recommend that shareholders vote FOR incumbent nominees Fioravanti and Hausman, as they are the most recent additions to the board, having joined in April of 2025, and we therefore do not hold them accountable for the Company's missteps.'
Your vote is important, no matter how many or how few shares of common stock you own. Ortelius urges you to sign, date, and return the WHITE universal proxy card today to vote 'FOR' the election of all six Ortelius nominees and in accordance with Ortelius' recommendations on the other proposals on the agenda for the Annual Meeting.
Stockholders who have questions or require assistance in voting their WHITE Proxy Card, or those who require copies of Ortelius' proxy materials, should contact: Saratoga Proxy Consulting LLC at (888) 368-0379 or info@saratogaproxy.com
*Permission to use quotations from the Egan-Jones report was neither sought nor obtained.
Additional Information
Ortelius Advisors, L.P., together with the other participants in its proxy solicitation (collectively, 'Ortelius'), has filed a definitive proxy statement and accompanying WHITE universal proxy card with the Securities and Exchange Commission ('SEC') to be used to solicit votes for the election of Ortelius' slate of highly-qualified director nominees at the 2025 annual meeting of stockholders (the 'Annual Meeting') of Brookdale Senior Living Inc., a Delaware corporation (the 'Company'). Stockholders are advised to read the proxy statement and any other documents related to the solicitation of stockholders of the Company in connection with the Annual Meeting because they contain important information, including information relating to the participants in Ortelius' proxy solicitation. These materials and other materials filed by Ortelius with the SEC in connection with the solicitation of proxies are available at no charge on the SEC's website at http://www.sec.gov. The definitive proxy statement and other relevant documents filed by Ortelius with the SEC are also available, without charge, by directing a request to Ortelius' proxy solicitor, Saratoga Proxy Consulting LLC, at its toll-free number (888) 368-0379 or via email at info@saratogaproxy.com.
Ortelius is a research-intensive, fundamental-based, activist-oriented alternative investment management firm focused on event-driven opportunities.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

White House officials defend Trump's firing of BLS chief
White House officials defend Trump's firing of BLS chief

The Hill

time7 minutes ago

  • The Hill

White House officials defend Trump's firing of BLS chief

White House officials on Sunday defended President Trump's decision to fire the head of the Bureau of Labor Statistics (BLS) following a weak jobs report, a move that has sparked broad criticism. 'The president wants his own people there so that when we see the numbers, they're more transparent and more reliable,' Kevin Hassett, chair of the National Economic Council, said on NBC's 'Meet the Press.' Hassett said in another interview on 'Fox News Sunday' that the BLS commissioner has a responsibility to explain major revisions such as the one seen in Friday's jobs report, which showed 258,000 fewer jobs for prior months than initially reported. 'The big downward revision is something of a puzzle. I don't think it was explained very well. And I think that markets might be as much unsettled by the fact that the data are so noisy,' Hassett said. U.S. Trade Representative Jamieson Greer, one of Trump's top tariff negotiators, said in an interview that aired on CBS's 'Face the Nation' Sunday that the president has 'real concerns' about the jobs numbers reported by the Labor Department. 'Even last year during the campaign, there were enormous swings in the jobs numbers, and so sounds to me like the president has real concerns. You know, not just based on today's, but everything we saw last year,' Greer said in the interview taped on Friday. 'You want to be able to have somewhat reliable numbers,' he added. 'There are always revisions, but sometimes you see these revisions go in really extreme ways. And it's, you know, the president is the president. He can choose who works in the executive branch.' Trump on Friday directed his team to fire BLS Commissioner Erika McEntarfer after the latest jobs report showed the country only adding 73,000 jobs in July, and major revisions for jobs added in May and June. The move prompted immediate outcry from Democrats and a handful of Republicans, with some calling for an investigation. McEntarfer was nominated by former President Biden and overwhelmingly confirmed by the GOP-led Senate early last year in an 86-8 vote. Trump's advisers underscored the president's concerns about revisions to the labor data while defending McEntarfer's firing. Hassett noted that jobs data reported by the government has seen major swings since the COVID-19 pandemic. 'What we've seen over the last few years is massive revisions to the jobs numbers. In fact, they were extremely reliable, the kind of numbers that you want to guide policy decisions and markets, through COVID. And then when COVID happened, because response rates went down a lot, then revision rates skyrocketed. So the typical monthly revision often was bigger than the number itself,' Hassett said on NBC. Trump, in axing the BLS chief, claimed without evidence that McEntarfer 'faked the Jobs Numbers' before the 2024 election in order to boost former Vice President Kamala Harris's White House bid, citing labor statistics revisions during the Biden administration that boosted job numbers ahead of the election. The president accused her of manipulating data to make him and Republicans look bad, writing on Truth Social on Friday, 'She will be replaced with someone much more competent and qualified. Important numbers like this must be fair and accurate, they can't be manipulated for political purposes.' McEntarfer reacted to Trump's firing of her in a social media post over the weekend, saying it was the 'honor of my life' to serve in the role and hailing the 'vital and important work' carried out by civil servants at the agency.

2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run
2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run

Yahoo

time35 minutes ago

  • Yahoo

2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run

Key Points Hims & Hers Health is unlocking new sources of growth potential, and its balance sheet is flourishing. Doximity is a prime platform for advertisers, and the profits are pouring in. 10 stocks we like better than Hims & Hers Health › It's been a wild first half of the year for stocks in 2025, but finding the right companies for your portfolio is a very personal process. You need to consider the type of stocks you want to buy, the industries and sectors you gravitate toward, the amount of capital you have to invest, and your own personal risk tolerance. If you have cash to invest in the stock market right now, and you're looking for growth stocks that could make smart additions to the basket of businesses you own, there are names to be found across a range of industries, including healthcare. Here are two healthcare stocks that have at least doubled over the past 12 months but still look poised to deliver favorable returns for shareholders in the next three to five years. 1. Hims & Hers Health Hims & Hers Health (NYSE: HIMS) has witnessed a stock run-up of more than 200% over the trailing-12-month period. In contrast, the S&P 500 is up only about 18% in that same time frame. This boom in the company's share price has occurred for a few reasons. Investors were particularly excited about the company's ability to offer affordable, compounded GLP-1 drugs for weight loss amid shortages of branded versions, and that fueled significant revenue growth and share-price appreciation. However, Hims & Hers can no longer mass-produce compounded drugs like semaglutide because the U.S. Food and Drug Administration declared the shortage resolved. While the company may still offer personalized doses where clinically applicable, its primary weight loss offerings are shifting to oral medications and liraglutide. In fact, Novo Nordisk, the maker of Wegovy (semaglutide for weight) and Ozempic (semaglutide for diabetes), ended its partnership with Hims & Hers, citing concerns over the latter company's promotion and sales of compounded semaglutide. While the company's offerings may evolve in the coming months and years, it has other sources of growth to lean on besides the weight loss segment. Hims & Hers' areas of focus include sexual health, hair loss, dermatology, mental health, and primary care. The platform also provides access to both over-the-counter and prescription treatments via online consultations with licensed healthcare professionals, and most of its revenue still comes from recurring subscriptions paid by healthcare consumers. The recent acquisition of Zava, a European digital health platform, seems to have boosted investor confidence in the future of the business outside of its ambitions in the weight loss industry. The addition of Zava to Hims & Hers' ecosystem will expand its reach into the U.K., Ireland, France, and Germany. Hims & Hers also plans to launch its platform in Canada in 2026. Revenue grew by 110% year over year in the first quarter, and the company is building upon an improving track record of profitability. Hims & Hers also delivered free cash flow of about $50 million in Q1. This business has a lot of potential. 2. Doximity Doximity (NYSE: DOCS) has seen shares pop by a bit more than 100% since this time one year ago. Doximity is known as the largest digital platform for U.S. medical professionals. It serves as a professional and social network for healthcare professionals including doctors, nurse practitioners, and physician assistants, and offers a wide variety of tools for communication, news, and career management. Doximity provides a curated newsfeed with the latest medical news and research relevant to different specialties, and also offers tools for job searches, salary comparisons, and reputation management. The platform even provides telehealth solutions, enabling virtual patient visits and consultations. The platform is free for healthcare professionals to use. This free access includes Doximity Dialer, a feature that allows secure communication with patients using a customized calling tool. The platform also offers free digital fax lines and access to Doximity Scribe, an AI-powered note-taking tool for verified clinicians. So, how does Doximity make money? From advertising and selling information. Doximity's platform is a prime digital marketing and advertising tool for pharmaceutical manufacturers and healthcare systems (like hospitals). These entities pay Doximity to advertise and promote their products and services to targeted medical professionals. Health systems and medical recruiting firms also pay Doximity to access its database of medical professionals for recruitment and hiring purposes. In Doximity's fiscal 2025, which ended March 31, revenue increased 20% from the prior fiscal year to $570.4 million. The company reported net income of $223.2 million, up 51% year over year, with free cash flow spiking 50% to $266.7 million. This healthcare stock is really an advertising business at its core, and a profitable one at that. These factors could induce some investors to take another long look at this top stock and I think it has room to run. Do the experts think Hims & Hers Health is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Hims & Hers Health make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Rachel Warren has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Doximity and Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run was originally published by The Motley Fool 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

KBR Investor News: If You Have Suffered Losses in KBR, Inc. (NYSE: KBR), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
KBR Investor News: If You Have Suffered Losses in KBR, Inc. (NYSE: KBR), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Business Upturn

timean hour ago

  • Business Upturn

KBR Investor News: If You Have Suffered Losses in KBR, Inc. (NYSE: KBR), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Aug. 03, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of KBR, Inc. (NYSE: KBR) resulting from allegations that KBR may have issued materially misleading business information to the investing public. SO WHAT: If you purchased KBR securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. WHAT IS THIS ABOUT: On June, 20, 2025, before the market opened, KBR issued a press release entitled 'KBR Announcement on HomeSafe Alliance Global Household Goods Contract.' The press release stated that 'HomeSafe Alliance, a KBR (NYSE: KBR) Joint Venture, informed us on June 18, 2025, that U.S. Transportation Command (TRANSCOM) has terminated HomeSafe's role in the Global Household Goods Contract, a contract designed to improve the moving system for military service members and their families.' On this news, KBR's stock fell $3.85 per share, or 7.2%, to close at $48.93 per share on June 20, 2025. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ——————————- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store